TG Therapeutics | TGTX - Current Liabilities

Stock Price
36.62
Daily Change
-0.30 -0.81%
Monthly
15.08%
Yearly
-11.40%
Q2 Forecast
35.84

TG Therapeutics reported $153.76M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Alaunos Therapeutics USD 921K 153K Sep/2025
Amgen USD 25.49B 3.7B Dec/2025
Ardelyx USD 88.6M 5.22M Dec/2025
Arrowhead Research USD 347.42M 151.94M Dec/2025
Bayer EUR 32.58B 3.63B Dec/2025
Biogen USD 3.35B 59.4M Dec/2025
Corcept Therapeutics USD 166.08M 6.18M Dec/2025
Curis USD 14.08M 5.3M Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
Infinity Pharmaceuticals USD 12.06M 775K Jun/2023
J&J USD 57.72B 3.59B Mar/2026
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Novartis USD 27.28B 4.72B Dec/2025
Novavax USD 459.95M 30.08M Dec/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Roche Holding CHF 28B 421M Dec/2025
TG Therapeutics USD 153.76M 3.05M Dec/2025
Verastem USD 72.27M 12.56M Dec/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025